TOH edition: Tuesday, 8 September 2026 · Health & Medicine
Even When Chemotherapy Stops Working, a Newly Approved Medicine Is Doubling Survival for Pancreatic Cancer Patients
Reported by Good News Network
Publisher date:
The FDA has granted immediate approval to daraxonrasib, an insurance-covered therapy shown to double survival times for people facing advanced pancreatic cancer after standard chemotherapy has failed. While not a permanent cure, the drug provides meaningful additional months of living time against an illness historically considered among the most untreatable. The decision delivers an immediate, accessible lifeline to patients and families who previously had exhausted their clinical options.
A newly approved, covered treatment doubles survival for late-stage pancreatic cancer when chemotherapy stops working, turning one of oncology's most devastating dead ends into a disease patients can actively fight for longer.
Read the original report at Good News Network (opens in a new tab) →
Read the full front page of Tuesday, 8 September 2026 →
Get tomorrow's front page
Five reasons to believe in progress, delivered once a day.